Roche lauds new flu drug trial as Tamiflu suffers generics hit

FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann/File Photo

ZURICH (Reuters) – Swiss drugmaker Roche’s hopes of regaining ground in the influenza market have been boosted after a late-stage study showed its investigational drug baloxavir marboxil reduced symptoms in people at high risk of complications. Analysts, however, said there was only a marginal benefit while there were cheaper generic copies of Roche’s older Tamiflu […]

Continue reading this article with a Fiji Times online membership.

More Stories